Compare Merck & Co., Inc. (MRK) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs NIO Inc. — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while NIO Inc. trades at $3.6 (market cap $8.62B). The key difference: Merck & Co., Inc. is far larger — about 40.8× NIO Inc.'s market cap, and Merck & Co., Inc. pays a 2.39% dividend while NIO Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and NIO Inc. for 81 Days on average.
| MRK | NIO | |
|---|---|---|
Market Cap | $351.28B | $8.62B |
Volume | 7,969,665 | 39,648,517 |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $7.46 |
52-Week Low | $82.49 | $3.37 |
Typical Hold Time | 98 Days | 81 Days |
Enterprise Value | $398.04B | $6.52B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
NIO trades at $3.60, up 1.69% today but near 52-week lows, with technical indicators showing bearish momentum. The company reported Q3 2026 deliveries up 25.4% and recently completed a strategic battery-swapping partnership with Geely. Despite revenue growth to $87.49B in 2025, NIO continues to post significant losses with a -17.8% net margin. Analyst consensus remains positive with a $6.23 price target, though technical signals and cash flow challenges present headwinds.
NIO's growth trajectory and strategic partnerships offer long-term potential, but investors face substantial execution risks amid persistent losses and competitive pressures. The stock's current discount to analyst targets presents opportunity, but requires careful monitoring of profitability improvements and market share sustainability in the crowded EV sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
